From accelerating scientific breakthrough and spotting previously elusive patterns in unwieldy global data masses, to enabling greater drug personalisation, AI and machine learning could help change the role and business models of life sciences in future, as part of a broader transformation of the health value chain. Siniša Belina of AMPLEXOR Life Sciences explores some of the potential opportunities, and considers how companies might start to prepare for what lies ahead.